ESR1 and breast cancer: In patients with breast cancer, immunohistochemistry analysis of primary and metastatic lesions reveals a modest reduction in ER levels and a significant decline in PR levels following endocrine therapy, leading to complete loss of PR expression in up to half of the tumors as resistance develops.